Back to search

Article

Targeted Nanoparticles: an Innovative Modality in the Treatment of Cancer

2025-12-02

Abstract excerpt

<h4>ABSTRACT</h4> Despite progress made in the development of anticancer therapeutics, traditional small-molecule chemotherapeutics often struggle to overcome toxicity, efficacy, and off-target effects. These specific issues can be overcome by either encapsulating the drug or by targeting it directly to the tumor cell. Here, we describe a novel targeted nanoparticle (referred to as a nano-antibody-drug conjugate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1d228049-8b2e-5743-aa27-a7815db7c843
DOI
10.64898/2025.12.01.691687
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeted Nanoparticles: an Innovative Modality in the Treatment of CancerDOI 10.64898/2025.12.01.691687
Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of NeuroblastomaSemantic proximity
Exploring the Potentials of Antibody–siRNA Conjugates in Tumor Cell Gene Silencing without Cationic AssistanceSemantic proximity
An overview of targeted cancer therapySemantic proximity
The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity
Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: A first-in-human phase 1 trialSemantic proximity
Advances in Cancer Treatment through Nanotheranostics and Emerging TherapiesSemantic proximity
Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Semantic proximity
Patritumab deruxtecan induces immunogenic cell deathSemantic proximity
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity
Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity
<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity
Select a neighboring publication to make it the new centre.